Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Isaacson

Cardiovascular Disease Jonesboro, AR Medical Doctor

NPI 1972572097 CMS profile 44342

4802 E Johnson Ave, Jonesboro, AR 72401

Open in the dashboard

General payments

$4,786

269 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$125,972 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Michael Isaacson of Jonesboro, AR is reported in the CMS Open Payments database as having received $4,786 across 269 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $125,972 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 68th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $32 1
2024 General $255 14
2023 General $1,209 61
2022 General $1,639 86
2021 General $982 63
2020 General $324 19
2019 General $345 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Isaacson
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Michael Isaacson were reported at $32. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Michael Isaacson Cardiovascular Disease median Middle half National median
2019 $345 $450 $127–$1,392 $163
2020 $324 $242 $77–$751 $114
2021 $982 $335 $101–$1,037 $132
2022 $1,639 $395 $121–$1,211 $149
2023 $1,209 $443 $136–$1,283 $160
2024 $255 $450 $136–$1,323 $164
2025 $32 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $703 43 payments
  2. Novartis Pharmaceuticals Corporation $643 41 payments
  3. Amgen Inc. $455 31 payments
  4. Janssen Pharmaceuticals, Inc $410 30 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $399 24 payments
  6. Abbott Laboratories $382 13 payments
  7. Merck Sharp & Dohme Corporation $293 18 payments
  8. Daxor Corporation $165 1 payment
  9. E.R. Squibb & Sons, L.L.C. $153 10 payments
  10. Edwards Lifesciences Corporation $148 1 payment
  11. Other $1,035 57 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,762 267 payments
  2. Education $24 2 payments
Products named General payments · program years 2019–2025
  1. ELIQUIS $687 42 payments
  2. Repatha $455 31 payments
  3. XARELTO $410 30 payments
  4. JARDIANCE $363 22 payments
  5. ENTRESTO $331 22 payments
  6. VERQUVO Cardiovascular $316 19 payments
  7. PAXLOVID $224 14 payments
  8. LEQVIO $219 13 payments
  9. VERQUVO Cardiovascular $203 12 payments
  10. Corlanor $176 11 payments
  11. Other $2,685 128 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 46 drugs

Part D claims

3,899

Median for Cardiology: 2,533

Drug cost

$576,133

Median for Cardiology: $485,213

Branded share of claims

29.6%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 373 $297,293
Entresto Sacubitril/Valsartan Brand 87 $76,132
Jardiance Empagliflozin Brand 95 $68,379
Repatha Sureclick Evolocumab Brand 72 $52,668
Brilinta Ticagrelor Brand 41 $19,834
Xarelto Rivaroxaban Brand 19 $11,540
Praluent Pen Alirocumab Brand 13 $6,256
Rosuvastatin Calcium Generic 460 $4,996
Ranolazine Er Ranolazine Brand 30 $3,931
Amlodipine-Atorvastatin Amlodipine/Atorvastatin Brand 14 $3,299

The 10 drugs with the highest cost, of 46 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$18,053

Medicare's payments for the services billed

Medicare patients

394

Average age 77

Services billed

747

189 women, 205 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 61%
Arthritis 61%
Atrial fibrillation 45%
Heart failure 42%
Diabetes 41%
Chronic kidney disease 34%
Depression 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INJECTAFER
  • Daiichi Sankyo Inc. $38
$38 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $36
$36 95 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $28
$28 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $23
$23 — —
RYBELSUS
  • Novo Nordisk Inc $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

269 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record